Search results
Results from the WOW.Com Content Network
Osteoporosis, including drug- and cancer-related osteoporosis, giant cell tumour of bone and hypercalcaemia of malignancies: Hypercholesterolaemia, cataract, urinary retention, hypocalcaemia, osteonecrosis of the jaw and anaphylaxis. Gemtuzumab ozogamicin: IV: CD33 antibody that induces apoptosis of the tagged cell. Acute myeloid leukaemia
"DNA synthesis in multiple myeloma cells following cell cycle-nonspecific chemotherapy". Cancer Res. 34 (11): 2911– 4. PMID 4424360. Ozawa S, Sugiyama Y, Mitsuhashi Y, Kobayashi T, Inaba M (1988). "Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration--time product". Cancer Chemother. Pharmacol.
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]
This is because the brain has an extensive system in place to protect it from harmful chemicals. Drug transporters can pump out drugs from the brain and brain's blood vessel cells into the cerebrospinal fluid and blood circulation. These transporters pump out most chemotherapy drugs, which reduces their efficacy for treatment of brain tumors.
Generally, drugs outlined within the ATC code L01 should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Antineoplastic agents .
Dose-dense chemotherapy is a chemotherapy treatment plan in which drugs are given with less time between treatments than in a standard chemotherapy treatment plan. [ 1 ] The Gompertzian model of tumor cell growth shows tumor cells growing fastest when the tumor is small.
Blinatumomab linking a T cell to a malignant B cell.. Blinatumomab is a bispecific T-cell engager (BiTE). [7] It enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells.
Busulfan was approved by the US Food and Drug Administration (FDA) for treatment of chronic myeloid leukemia (CML) in 1999. Busulfan was the mainstay of the chemotherapeutic treatment of chronic myeloid leukemia (CML) until it was displaced by the new gold standard, imatinib, though it is still in use to a degree as a result of the drug's relative low cost.